Core Viewpoint - The Hong Kong stock market is experiencing significant volatility, with southbound capital showing dramatic fluctuations, including a net outflow of over 18 billion HKD followed by a substantial inflow of 234.25 billion HKD, indicating a strong long-term investment trend despite short-term adjustments [1][2]. Group 1: Market Trends - The Hang Seng Index and Hang Seng Tech Index have seen maximum drawdowns of 5.3% and 7.79% respectively in the last 10 trading days as of August 5 [2]. - Year-to-date, southbound capital has flowed into the Hong Kong market totaling 884.38 billion HKD, surpassing the total inflow for the entire previous year of 807.87 billion HKD, marking a historical high [3][4]. - The trend of investing in Hong Kong stocks through ETFs has surged, with the total scale of 79 Hong Kong Stock Connect-themed ETFs reaching 238.16 billion HKD, nearly doubling from 81.99 billion HKD at the end of last year [3]. Group 2: Institutional Insights - Institutional consensus remains optimistic about the long-term value of the Hong Kong stock market, particularly in the technology sector, which is expected to attract future capital due to its high growth potential and technological barriers [1][3]. - Public funds have increased their allocation to Hong Kong stocks, with over 1,700 funds raising their positions in the second quarter, and the proportion of public fund holdings in Hong Kong stocks reaching a new high of 39.8% [4][5]. Group 3: Investment Strategies - The current investment logic in the Hong Kong market has shifted towards structural opportunities, with significant increases in holdings in sectors such as pharmaceuticals, banking, and non-bank financials [6]. - The market is witnessing a valuation uplift driven by policy benefits, global liquidity, and market sentiment, with a focus on high-quality development and new productive forces [6][7]. - There is a growing expectation of "converging trades" between A-shares and Hong Kong stocks, particularly in small-cap stocks, as interest from southbound investors increases [7][8].

智通财经APP讯，石药集团(01093)发布公告，公司附属公司石药集团百克(山东)生物制药股份有限公司 开发的司美格鲁肽注射液(该产品)的上市申请已获中国国家药品监督管理局受理。本次申报的适应症为 成人2型糖尿病患者的血糖控制。 基于在疗效、安全性、制剂等方面的优势，该产品具有显著的临床应用价值。集团也在积极推进该产品 针对肥胖╱超重适应症的Ⅲ期临床试验，以期使更多患者从中获益。 该产品是基于天然人胰高血糖素样肽-1(GLP-1)结构的胰高血糖素样肽-1受体激动剂，为化学合成法制 备的司美格鲁肽制剂，按照化药注册分类2.2类新药申报，属含有已知活性成份的新处方工艺且具有明 显临床优势的药品。GLP-1是由肠道L细胞分泌的肠源性激素，可通过与广泛分布于全身多种器官和组 织的GLP-1受体结合而发挥作用，并通过多重机制实现降糖、减重以及心血管和肾脏保护等方面的综合 获益。 本次申请基于一项关键性Ⅲ期临床试验。该临床试验结果表明，在经二甲双胍治疗血糖控制不佳的2型 糖尿病患者中，与诺和诺德开发的司美格鲁肽相比，该产品展现出高度一致的疗效，且其胃肠道反应发 生率略低。该产品遵循相关指导原则，通过药学、非临床、临床药代 ...

每经AI快讯，8月5日，石药集团公告，附属公司石药集团百克(山东)生物制药股份有限公司开发的司美 格鲁肽注射液的上市申请已获国家药品监督管理局受理。本次申报的适应症为成人2型糖尿病患者的血 糖控制。 ...

Core Viewpoint - The company has received acceptance for the listing application of its semaglutide injection, aimed at controlling blood sugar levels in adults with type 2 diabetes, from the National Medical Products Administration of China [1] Group 1: Product Development - The semaglutide injection is a GLP-1 receptor agonist developed based on the natural structure of human glucagon-like peptide-1, classified as a new drug under category 2.2, which contains known active ingredients and demonstrates significant clinical advantages [1] - The application is based on a pivotal phase III clinical trial, which showed that the product exhibited highly consistent efficacy compared to Novo Nordisk's semaglutide in patients with poorly controlled blood sugar after metformin treatment, with slightly lower gastrointestinal reaction rates [1] Group 2: Clinical Value and Future Prospects - The product has significant clinical application value due to its advantages in efficacy, safety, and formulation [2] - The company is actively advancing phase III clinical trials for the product targeting obesity/overweight indications, aiming to benefit more patients [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 獲國家藥品監督管理局受理 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布，本公司附屬公司石藥集團百克（ 山東 ）生物製藥股份有限公司開發的司美格魯肽注射液 （「該產品」）的上市申請已獲中華人民共和國國家藥品監督管理局受理。本次申報的適應症 為成人2型糖尿病患者的血糖控制。 該產品是基於天然人胰高血糖素樣肽-1（「GLP -1」）結構的胰高血糖素樣肽-1受體激動劑， 為化學合成法製備的司美格魯肽製劑，按照化藥註冊分類2.2類新藥申報，屬含有已知活性 成份的新處方工藝且具有明顯臨床優勢的藥品。GLP -1是由腸道L細胞分泌的腸源性激素， 可通過與廣泛分布於全身多 種器官和組織的GLP -1受體結合而發揮 作用，並通過多重機制 實現降糖、減重以及心血管和腎臟保護等方面的綜合獲益。 本次申請基於一項關鍵性Ⅲ ...

Core Points - The CSI Hong Kong Stock Connect Pharmaceutical Index has shown significant growth, with a 12.87% increase over the past month, 43.55% over the past three months, and a 67.00% increase year-to-date [1] Group 1: Index Performance - The CSI Hong Kong Stock Connect Pharmaceutical Index is currently at 3339.75 points [1] - The index is based on a sample of securities classified according to the China Securities Index industry classification standards [1] Group 2: Index Composition - The top ten weighted stocks in the index include China Biologic Products (18.53%), BeiGene (13.57%), and CSPC Pharmaceutical Group (13.41%) [1] - The index is composed entirely of stocks listed on the Hong Kong Stock Exchange, with 100.00% market share [1] - The index's holdings are primarily in drug formulations (95.80%) and raw materials (4.20%) [1] Group 3: Index Adjustment - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, unless there are special events affecting the index [2]

金融界8月5日消息，上证指数高开高走，中证港股通生物科技主题指数 (港股通生物科技，932253)报 1886.25点。 数据统计显示，中证港股通生物科技主题指数近一个月上涨22.20%，近三个月上涨54.39%，年至今上 涨108.66%。 据了解，中证港股通生物科技主题指数从港股通范围内选取50只业务涉及生物药品、制药与生物科技服 务等领域的上市公司证券作为指数样本，以反映港股通范围内生物科技主题上市公司证券的整体表现。 该指数以2018年12月28日为基日，以1000.0点为基点。 从指数持仓来看，中证港股通生物科技主题指数十大权重分别为：百济神州（13.23%）、信达生物 （12.79%）、药明生物（9.82%）、康方生物（8.87%）、中国生物制药（6.39%）、石药集团 （6.11%）、三生制药（4.69%）、翰森制药（3.27%）、药明康德（3.03%）、科伦博泰生物-B （2.67%）。 本文源自：金融界 作者：行情君 从中证港股通生物科技主题指数持仓的市场板块来看，香港证券交易所占比100.00%。 从中证港股通生物科技主题指数持仓样本的行业来看，化学药占比40.03%、生物药品占比38.7 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Insights - The pharmaceutical and biotechnology industry index increased by 4.90%, ranking third among 31 primary industries, outperforming the CSI 300 index, which decreased by 0.09% [4][15] - The sub-industries of medical research outsourcing and vaccines saw significant gains of 12.70% and 6.59%, respectively, while blood products and offline pharmacies lagged with increases of only 0.35% and 2.41% [4][15] - As of August 1, 2025, the overall PE (TTM) for the pharmaceutical and biotechnology industry was 30.97x, up from 30.09x in the previous period, indicating an upward valuation trend [4][21] - The top three sub-industries by PE (TTM) are vaccines (62.06x), hospitals (38.94x), and other biological products (38.44x), while the lowest valuation is in pharmaceutical circulation (16.12x) [4][21] Industry Review - The National Medical Products Administration (NMPA) is seeking public opinion on the "Regulations on the Filing Management of Internet Drug and Medical Device Information Services" [6] - The State Council's news office held a press conference discussing multiple measures for drug price management [6] - Bristol-Myers Squibb's "Nivolumab Injection" combined with "Ipilimumab Injection" received NMPA approval, marking it as China's first approved dual immune therapy for lung cancer [6] - The total transaction amount for innovative drug BD in China exceeded 60 billion USD in the first half of 2025, indicating a significant market shift towards platform-based pipeline output [7] Investment Recommendations - The National Healthcare Security Administration (NHSA) has clarified a "reverse inward competition" direction in the 11th batch of centralized procurement, promoting a shift from price competition to a quality-first and reasonably priced ecosystem [7] - The report suggests focusing on companies with "true innovation" capabilities, strong barriers (complex formulations/high-end device domestic replacements), platform-based operations, and internationalization [7]

Investment Rating - The report maintains a rating of "B" for the biopharmaceutical industry, indicating expected volatility greater than the benchmark index [1]. Core Insights - The biopharmaceutical industry has shown significant market performance over the past year, with innovative drug developments, particularly in the area of ADCs (Antibody-Drug Conjugates) for lung cancer treatment [1]. - PD-1/L1 combined with ADCs is expected to overcome resistance and improve overall response rates (ORR), with promising results from various clinical trials [3][4]. - The report highlights specific drugs such as sac-TMT, HLX43, and SYS6010, which have demonstrated significant efficacy and tolerability in treating NSCLC and SCLC [3][5]. Summary by Sections Market Performance - The biopharmaceutical industry has outperformed the market, driven by advancements in innovative therapies [1]. Clinical Trials and Efficacy - In first-line treatment for non-squamous NSCLC, sac-TMT combined with PD-L1 showed an ORR of 59.3% and a median progression-free survival (mPFS) of 15.0 months, compared to 9-10 months for chemotherapy combined with PD-1 [4]. - In second-line EGFR wild-type NSCLC, the ORR for the drug iza-bren was 50.0%, while SYS6010 achieved an ORR of 88.9% in previously treated EGFR-mutant NSCLC [5]. Drug Tolerability - The report notes that the common grade 3 or higher treatment-related adverse events (TRAE) for the mentioned drugs were primarily hematological toxicities, with specific rates of treatment discontinuation due to TRAE being 2.4% for iza-bren [3][5].

Core Insights - The A-share market continues to show strength, with the Shanghai Composite Index closing at 3617.6 points, marking a new high for the phase [1] - The Hong Kong innovative drug ETF (513120) achieved a trading volume exceeding 11 billion yuan, with a closing increase of 3.17%, leading the market in ETF performance [1] - The ETF has seen a year-to-date return of over 105%, with its latest scale surpassing 16 billion yuan, highlighting significant market interest in the innovative drug sector [1] Industry Performance - The strong performance of the Hong Kong innovative drug ETF is supported by robust fundamentals in the innovative drug industry, with major domestic companies like Heng Rui Medicine and CSPC Pharmaceutical securing over 10 billion USD in overseas licensing deals [1] - The National Medical Products Administration reported that 43 innovative drugs were approved in the first half of 2025, a 59% increase year-on-year, indicating a peak in industry innovation achievements [1] Market Valuation - The Hong Kong innovative drug ETF closely tracks the CSI Hong Kong Innovative Drug Index, focusing on leading companies in the innovative drug supply chain, with a high weight of 92.5% in biopharmaceuticals and chemical drugs [2] - The current TTM price-to-earnings ratio of the index is 40.06, positioned at the 42nd percentile historically, suggesting a favorable valuation [2] Future Outlook - Analysts are optimistic about the sustained opportunities in the innovative drug sector, with expectations of improved cash flow and a solid long-term growth logic for the industry [2] - The domestic pharmaceutical companies are transitioning from a following phase to true innovation and internationalization, with a positive outlook for the next decade as they increasingly participate in the global market [2] - The narrowing premium between A/H listed pharmaceutical companies is anticipated, with potential for a value reassessment of Hong Kong pharmaceutical assets as the innovation capabilities of Chinese companies continue to be realized [2]